Oculis Holding AG (NASDAQ:OCS) Given Average Rating of “Moderate Buy” by Brokerages

Oculis Holding AG (NASDAQ:OCS) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $43.8571.

Several research firms have weighed in on OCS. Stifel Nicolaus lifted their price objective on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright increased their target price on Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. began coverage on Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price for the company. Lifesci Capital began coverage on Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd.

Institutional Trading of Oculis

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new stake in shares of Oculis during the fourth quarter worth approximately $9,862,000. Millennium Management LLC acquired a new position in Oculis in the 4th quarter valued at approximately $312,000. NEXTBio Capital Management LP purchased a new stake in Oculis in the 4th quarter worth approximately $2,991,000. Marshall Wace LLP acquired a new stake in shares of Oculis during the 4th quarter valued at $914,000. Finally, Alyeska Investment Group L.P. boosted its stake in shares of Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares during the period. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Price Performance

OCS stock opened at $26.59 on Friday. Oculis has a one year low of $14.00 and a one year high of $30.68. The firm has a 50-day moving average of $27.43 and a two-hundred day moving average of $22.66. The firm has a market capitalization of $1.54 billion, a PE ratio of -11.71 and a beta of 0.29. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%. On average, analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.